Search

Your search keyword '"Romano, Marta"' showing total 6 results
Start Over Author "Romano, Marta" Publisher biomed central
6 results on '"Romano, Marta"'

1. Intranasal dexamethasone: a new clinical trial for the control of inflammation and neuroinflammation in COVID-19 patients

Author

Cárdenas, Graciela, Chávez-Canales, María, Espinosa, Ana María, Jordán-Ríos, Antonio, Malagon, Daniel Anica, Murillo, Manlio Fabio Márquez, Araujo, Laura Victoria Torres, Campos, Ricardo Leopoldo Barajas, Wong-Chew, Rosa María, González, Luis Esteban Ramirez, Cresencio, Karent Ibet, Velázquez, Enrique García, de la Cerda, Mariana Rodriguez, Leyva, Yoana, Hernández-Ruiz, Joselin, Hernández-Medel, María Luisa, León-Hernández, Mireya, Quero, Karen Medina, Monciváis, Anahí Sánchez, Díaz, Sergio Hernández, Martínez, Ignacia Rosalia Zeron, Martínez-Cuazitl, Adriana, Salazar, Iván Noé Martínez, Sarmiento, Eduardo Beltrán, Peña, Aldo Figueroa, Hernández, Patricia Saraí, Reynoso, Rafel Ignacio Aguilar, Reyes, Daniela Murillo, del Río Ambriz, Luis Rodrigo, Bonilla, Rogelio Antonio Alfaro, Cruz, Jocelyn, Huerta, Leonor, Fierro, Nora Alma, Hernández, Marisela, Pérez-Tapia, Mayra, Meneses, Gabriela, Espíndola-Arriaga, Erick, Rosas, Gabriela, Chinney, Alberto, Mendoza, Sergio Rosales, Hernández-Aceves, Juan Alberto, Cervantes-Torres, Jaquelynne, Rodríguez, Anai Fuentes, Alor, Roxana Olguin, Francisco, Sandra Ortega, Salazar, Evelyn Alvarez, Besedovsky, Hugo, Romano, Marta C., Bobes, Raúl J., Jung, Helgi, Soldevila, Gloria, López-Alvarenga, Juan, Fragoso, Gladis, Laclette, Juan Pedro, and Sciutto, Edda

Published
2022
Full Text
View/download PDF

2. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial

Author

Devos, Timothy, Geukens, Tatjana, Schauwvlieghe, Alexander, Ariën, Kevin K., Barbezange, Cyril, Cleeren, Myriam, Compernolle, Veerle, Dauby, Nicolas, Desmecht, Daniël, Grimaldi, David, Lambrecht, Bart N., Luyten, Anne, Maes, Piet, Moutschen, Michel, Romano, Marta, Seyler, Lucie, Nevessignsky, Michel Toungouz, Vandenberghe, Katleen, van Griensven, Johan, Verbeke, Geert, Vlieghe, Erika, Yombi, Jean Cyr, Liesenborghs, Laurens, Verhamme, Peter, and Meyfroidt, Geert

Published
2020
Full Text
View/download PDF

3. Correction to: A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial

Author

Devos, Timothy, Geukens, Tatjana, Schauwvlieghe, Alexander, Ariën, Kevin K., Barbezange, Cyril, Cleeren, Myriam, Compernolle, Veerle, Dauby, Nicolas, Desmecht, Daniël, Grimaldi, David, Lambrecht, Bart N., Luyten, Anne, Maes, Piet, Moutschen, Michel, Romano, Marta, Seyler, Lucie, Nevessignsky, Michel Toungouz, Vandenberghe, Katleen, van Griensven, Johan, Verbeke, Geert, Vlieghe, Erika, Yombi, Jean Cyr, Liesenborghs, Laurens, Verhamme, Peter, and Meyfroidt, Geert

Published
2020
Full Text
View/download PDF

4. A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial.

Author

UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service de médecine interne générale, Devos, Timothy, Geukens, Tatjana, Schauwvlieghe, Alexander, Ariën, Kevin K, Barbezange, Cyril, Cleeren, Myriam, Compernolle, Veerle, Dauby, Nicolas, Desmecht, Daniël, Grimaldi, David, Lambrecht, Bart N, Luyten, Anne, Maes, Piet, Moutschen, Michel, Romano, Marta, Seyler, Lucie, Nevessignsky, Michel Toungouz, Vandenberghe, Katleen, van Griensven, Johan, Verbeke, Geert, Vlieghe, Erika, Yombi, Jean Cyr, Liesenborghs, Laurens, Verhamme, Peter, Meyfroidt, Geert, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Service de médecine interne générale, Devos, Timothy, Geukens, Tatjana, Schauwvlieghe, Alexander, Ariën, Kevin K, Barbezange, Cyril, Cleeren, Myriam, Compernolle, Veerle, Dauby, Nicolas, Desmecht, Daniël, Grimaldi, David, Lambrecht, Bart N, Luyten, Anne, Maes, Piet, Moutschen, Michel, Romano, Marta, Seyler, Lucie, Nevessignsky, Michel Toungouz, Vandenberghe, Katleen, van Griensven, Johan, Verbeke, Geert, Vlieghe, Erika, Yombi, Jean Cyr, Liesenborghs, Laurens, Verhamme, Peter, and Meyfroidt, Geert

Abstract

BACKGROUND: The COVID-19 pandemic has imposed an enormous burden on health care systems around the world. In the past, the administration of convalescent plasma of patients having recovered from SARS and severe influenza to patients actively having the disease showed promising effects on mortality and appeared safe. Whether or not this also holds true for the novel SARS-CoV-2 virus is currently unknown. METHODS: DAWn-Plasma is a multicentre nation-wide, randomized, open-label, phase II proof-of-concept clinical trial, evaluating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19 in Belgium. Patients hospitalized with a confirmed diagnosis of COVID-19 are eligible when they are symptomatic (i.e. clinical or radiological signs) and have been diagnosed with COVID-19 in the 72 h before study inclusion through a PCR (nasal/nasopharyngeal swab or bronchoalveolar lavage) or a chest-CT scan showing features compatible with COVID-19 in the absence of an alternative diagnosis. Patients are randomized in a 2:1 ratio to either standard of care and convalescent plasma (active treatment group) or standard of care only. The active treatment group receives 2 units of 200 to 250 mL of convalescent plasma within 12 h after randomization, with a second administration of 2 units 24 to 36 h after ending the first administration. The trial aims to include 483 patients and will recruit from 25 centres across Belgium. The primary endpoint is the proportion of patients that require mechanical ventilation or have died at day 15. The main secondary endpoints are clinical status on day 15 and day 30 after randomization, as defined by the WHO Progression 10-point ordinal scale, and safety of the administration of convalescent plasma. DISCUSSION: This trial will either provide support or discourage the use of convalescent plasma as an early intervention for the treatment of hospitalized patients with COVID-19 inf

Published
2020

5. Correction to: A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial

Author

UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Centre de prise en charge (H.I.V.), UCL - (SLuc) Service de biochimie médicale, Devos, Timothy, Geukens, Tatjana, Schauwvlieghe, Alexander, Ariën, Kevin K., Barbezange, Cyril, Cleeren, Myriam, Compernolle, Veerle, Dauby, Nicolas, Desmecht, Daniël, Grimaldi, David, Lambrecht, Bart N., Luyten, Anne, Maes, Piet, Moutschen, Michel, Romano, Marta, Seyler, Lucie, Nevessignsky, Michel Toungouz, Vandenberghe, Katleen, van Griensven, Johan, Verbeke, Geert, Vlieghe, Erika, Yombi, Jean Cyr, Liesenborghs, Laurens, Verhamme, Peter, Meyfroidt, Geert, UCL - SSS/IREC/SLUC - Pôle St.-Luc, UCL - (SLuc) Centre de prise en charge (H.I.V.), UCL - (SLuc) Service de biochimie médicale, Devos, Timothy, Geukens, Tatjana, Schauwvlieghe, Alexander, Ariën, Kevin K., Barbezange, Cyril, Cleeren, Myriam, Compernolle, Veerle, Dauby, Nicolas, Desmecht, Daniël, Grimaldi, David, Lambrecht, Bart N., Luyten, Anne, Maes, Piet, Moutschen, Michel, Romano, Marta, Seyler, Lucie, Nevessignsky, Michel Toungouz, Vandenberghe, Katleen, van Griensven, Johan, Verbeke, Geert, Vlieghe, Erika, Yombi, Jean Cyr, Liesenborghs, Laurens, Verhamme, Peter, and Meyfroidt, Geert

Abstract

no abstract available

Published
2020

6. Overexpression of DosR in Mycobacterium tuberculosis does not affect aerobic replication in vitro or in murine macrophages.

Author

Flores-Valdez, Mario, Freches, Danielle, Bruffaerts, Nicolas, Romano, Marta, Schoolnik, Gary, Dolganov, Gregory, and Huygen, Kris

Abstract

Mycobacterium tuberculosis H37Rv, constitutively expressing a second copy of the transcriptional regulator DosR ( Rv3133c) under control of the hsp60 promoter, was compared to wild-type M. tuberculosis for in vitro expression of the target genes of the DosR dormancy regulon, for its in vitro growth characteristics in liquid 7H9 culture medium, and for its capacity to replicate in murine macrophages. Under aerobic conditions, hsp60-driven DosR significantly induced the expression of 39 out of 44 DosR regulon genes, as assessed by real time qPCR. Increased DosR regulon gene transcription in vitro did not modify the capacity of the strain to grow under axenic conditions nor to infect murine macrophages as compared to unmodified wild-type bacteria. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results